Akeso, Inc. (HKG:9926)
128.00
-3.50 (-2.66%)
Oct 10, 2025, 4:08 PM HKT
Akeso Revenue
Akeso had revenue of 1.41B CNY in the half year ending June 30, 2025, a decrease of -61.61%. This brings the company's revenue in the last twelve months to 2.51B, up 33.97% year-over-year. In the year 2024, Akeso had annual revenue of 2.12B, down -53.08%.
Revenue (ttm)
2.51B CNY
Revenue Growth
+33.97%
P/S Ratio
42.86
Revenue / Employee
827.26K CNY
Employees
3,035
Market Cap
117.91B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
Dec 31, 2021 | 225.63M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
WuXi Biologics | 21.98B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
CSPC Pharmaceutical Group | 28.49B |
Akeso News
- 26 days ago - Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Nasdaq
- 4 weeks ago - Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
- 6 weeks ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 6 weeks ago - Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results - GuruFocus
- 6 weeks ago - Akeso shares surge as cancer drug achieves key milestone in China trial - Seeking Alpha
- 4 months ago - Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback - South China Morning Post
- 5 months ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 5 months ago - China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug - South China Morning Post